IL131025A0 - Treatment of autoimmune disease using tolerization in combination with methotrexate - Google Patents

Treatment of autoimmune disease using tolerization in combination with methotrexate

Info

Publication number
IL131025A0
IL131025A0 IL13102598A IL13102598A IL131025A0 IL 131025 A0 IL131025 A0 IL 131025A0 IL 13102598 A IL13102598 A IL 13102598A IL 13102598 A IL13102598 A IL 13102598A IL 131025 A0 IL131025 A0 IL 131025A0
Authority
IL
Israel
Prior art keywords
tolerization
methotrexate
treatment
combination
autoimmune disease
Prior art date
Application number
IL13102598A
Other languages
English (en)
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Publication of IL131025A0 publication Critical patent/IL131025A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
    • B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
    • B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
    • B41J2/01—Ink jet
    • B41J2/21—Ink jet for multi-colour printing
    • B41J2/2107—Ink jet for multi-colour printing characterised by the ink properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0094—Colour printing
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0097—Printing on special media, e.g. labels, envelopes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL13102598A 1997-01-24 1998-01-26 Treatment of autoimmune disease using tolerization in combination with methotrexate IL131025A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3672297P 1997-01-24 1997-01-24
PCT/US1998/001648 WO1998032451A1 (en) 1997-01-24 1998-01-26 Treatment of autoimmune disease using tolerization in combination with methotrexate

Publications (1)

Publication Number Publication Date
IL131025A0 true IL131025A0 (en) 2001-01-28

Family

ID=21890248

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13102598A IL131025A0 (en) 1997-01-24 1998-01-26 Treatment of autoimmune disease using tolerization in combination with methotrexate

Country Status (10)

Country Link
EP (1) EP0994717A4 (ko)
JP (1) JP2001511134A (ko)
KR (1) KR20000070460A (ko)
AU (1) AU6648898A (ko)
BR (1) BR9807112A (ko)
CA (1) CA2278152A1 (ko)
HU (1) HUP0001960A2 (ko)
IL (1) IL131025A0 (ko)
NO (1) NO993600L (ko)
WO (1) WO1998032451A1 (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2314182T3 (es) 2002-02-11 2009-03-16 Antares Pharma, Inc. Inyector intradermico.
FI1850892T4 (fi) 2005-01-24 2023-08-31 Neula-avusteinen esitäytetyn ruiskun omaava suihkuinjektori
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
WO2007131025A1 (en) 2006-05-03 2007-11-15 Antares Pharma, Inc. Injector with adjustable dosing
US8251947B2 (en) 2006-05-03 2012-08-28 Antares Pharma, Inc. Two-stage reconstituting injector
ES2548447T3 (es) 2008-03-10 2015-10-16 Antares Pharma, Inc. Dispositivo de seguridad para inyector
JP5611208B2 (ja) 2008-08-05 2014-10-22 アンタレス・ファーマ・インコーポレーテッド 多数回服用量の注射装置
EP2408493B1 (en) 2009-03-20 2024-07-24 Antares Pharma, Inc. Hazardous agent injection system
KR101801864B1 (ko) 2010-06-16 2017-11-27 인플래머토리 리스폰스 리서치, 아이엔씨. 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
US8496619B2 (en) 2011-07-15 2013-07-30 Antares Pharma, Inc. Injection device with cammed ram assembly
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
PT2822618T (pt) 2012-03-06 2024-03-04 Antares Pharma Inc Seringa pré-cheia com característica de força de rutura
KR20150011346A (ko) 2012-04-06 2015-01-30 안타레스 팔마, 인코퍼레이티드 테스토스테론 조성물의 바늘-보조식 젯 주입 투여 장치 및 방법
US9364610B2 (en) 2012-05-07 2016-06-14 Antares Pharma, Inc. Injection device with cammed ram assembly
PT3659647T (pt) 2013-02-11 2024-03-27 Antares Pharma Inc Dispositivo de injeção a jato auxiliado por agulha tendo força de gatilho reduzida
CA2905031C (en) 2013-03-11 2018-01-23 Hans PFLAUMER Dosage injector with pinion system
WO2014165136A1 (en) 2013-03-12 2014-10-09 Antares Pharma, Inc. Constant volume prefilled syringes and kits thereof
WO2014164299A1 (en) 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
RU2672871C2 (ru) 2013-03-13 2018-11-20 Инфламматори Респонс Ресёрч, Инк. Применение левоцетиризина и монтелукаста при лечении травматических повреждений
CN105263579B (zh) 2013-03-13 2020-01-10 炎症反应研究公司 左西替利嗪和孟鲁司特在治疗血管炎中的用途
EP3193875B1 (en) 2014-09-15 2022-02-16 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
DE3856566T2 (de) * 1987-06-24 2004-06-24 Brigham And Women's Hospital, Boston Behandlung von Autoimmun-Erkrankungen durch orale Verabreichung von Autoantigenen
EP0503055A1 (en) * 1990-09-06 1992-09-16 Rijksuniversiteit Utrecht Inhibitor of lymphocyte response and immune-related disease
DE69332518T2 (de) * 1992-02-28 2003-09-04 Autoimmune Inc Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
WO1996040235A1 (en) * 1995-06-07 1996-12-19 Nexstar Pharmaceuticals, Inc. Method to use superantigens to target subpopulations of t cells
CA2224709C (en) * 1995-06-13 2009-05-12 Nippon Meat Packers, Inc. Oral drugs and functional foods for treating and preventing rheumatoid arthritis

Also Published As

Publication number Publication date
CA2278152A1 (en) 1998-07-30
KR20000070460A (ko) 2000-11-25
AU6648898A (en) 1998-08-18
BR9807112A (pt) 2001-09-18
EP0994717A1 (en) 2000-04-26
NO993600D0 (no) 1999-07-23
JP2001511134A (ja) 2001-08-07
NO993600L (no) 1999-09-23
EP0994717A4 (en) 2000-07-26
WO1998032451A1 (en) 1998-07-30
HUP0001960A2 (hu) 2000-10-28

Similar Documents

Publication Publication Date Title
IL131025A0 (en) Treatment of autoimmune disease using tolerization in combination with methotrexate
ZA989461B (en) Methods and compositions for the treatment of autoimmune disease using heat shock proteins
ZA9710339B (en) Xanthines and their therapeutic use
HUP0004439A3 (en) 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
EP0924983A4 (en) S (-) - TOLTERODINE FOR THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS
EP1165109A4 (en) AUTOIMMUNE DISEASE TREATMENT
EP0966386A4 (en) HUMAN TRACTION VEHICLE
HUP0102142A3 (en) Use of cyclosporins in the treatment of inflammatory autoimmune diseases
HUP0001276A2 (en) Illuminating body for swimming pools and similar
ZA984174B (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
IL113303A0 (en) Treatment of autoimmune disease using oral tolerization and/or type I interferon
IL113301A0 (en) Treatment of autoimmune disease using oral tolerization and/or TH2-enhancing cytokines
HUP9900147A3 (en) Therapeutic agents and autoimmune diseases
GB9419553D0 (en) Polypeptides and their use in the treatment of auto-immune disease
HK1025954A1 (en) Triptolide derivatives useful in the treatment of autoimmune diseases
EP0797440A4 (en) TREATING AUTOIMMUNE DISEASES WITH THE AID OF 2-AMINOPURINE DERIVATIVES
GB9621825D0 (en) Microparticles and their use as therapeutic vehicles
GB9705200D0 (en) Well treatment with particles
IL129460A0 (en) Use of lofexidine in the treatment of behavioral disorders
EP1073459A4 (en) COMPOSITIONS AND METHODS OF TOLERATING IN IMMUNOMOPLEX-MEDIATED ILLNESS
HUP9902802A3 (en) Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders
AU7262800A (en) Diagnostic and therapeutic methods in autoimmune disease
EP1020517A4 (en) A HUMAN CHONDROCYTE GENE
IL132845A0 (en) Non-myeloablative tolerogenic treatment
SI0983275T1 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases